Literature DB >> 24163806

Genotyping of Human Papillomavirus and TP53 Mutaions at Exons 5 to 7 in Lung Cancer Patients from Iran.

Hossein Jafari1, Reza Gharemohammadlou, Ashraf Fakhrjou, Ayyub Ebrahimi, Kazem Nejati-Koshki, Mahsa Nadri, Ebrahim Sakhinia.   

Abstract

INTRODUCTION: There is a powerful relationship between high-risk human papillomaviruses and lung cancer. In fact, inactivation of p53 is the most common genetic abnormality in lung cancer. Indeed, the frequency of HPV types and TP53 mutations in squamous cell carcinoma of lung, among patients from the northwest of Iran has been evaluated in this article. Methodes: Fifty Paraffin embedded blocks of lung SCC were selected for detection of HPV DNA by Nested PCR, and then DNA was sequenced for HPV typing. Equal numbers of positive and negative samples for the HPV DNA were examined for the presence of mutations in exons 5-7 of the TP53 gene by PCR and direct sequencing.
RESULTS: Overtly 9 (18%) of 50 samples presented the HPV DNA: eight were HPV-18 and one was HPV-6. TP53 mutations were found in 5 samples (27.7%). Of these, 4 cases showed mutations in exon 5 and one case contained a mutation in exon 7.The most frequent mutation in exon 5 was the C to G transversion (c.409C>G), and also the T to A tansversion (c.770T>A) in exon 7.
CONCLUSION: This study showed that HPV-18 is more likely to conscequence in the development of lung cancer among some communities. Genetic alterations, alongside with environmental factors, all play a significant role in the pathogenesis of lung cancer.

Entities:  

Keywords:  Human Papillomaviruses; Squamous Cell Carcinoma; TP53 Mutations

Year:  2013        PMID: 24163806      PMCID: PMC3786796          DOI: 10.5681/bi.2013.018

Source DB:  PubMed          Journal:  Bioimpacts        ISSN: 2228-5652


  25 in total

1.  DNA extraction from paraffin-embedded tissues.

Authors:  H Fan; M L Gulley
Journal:  Methods Mol Med       Date:  2001

Review 2.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

3.  Prevalence of human papillomaviruses in lung carcinomas: a study of 218 cases.

Authors:  Cyrille J Coissard; Guillaume Besson; Myriam C Polette; Michel Monteau; Philippe L Birembaut; Christine E Clavel
Journal:  Mod Pathol       Date:  2005-12       Impact factor: 7.842

4.  Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas.

Authors:  Yan Yu; Aimin Yang; Senke Hu; Jinghua Zhang; Hong Yan
Journal:  Clin Respir J       Date:  2012-01-06       Impact factor: 2.570

5.  Cancer occurrence in Iran in 2002, an international perspective.

Authors:  Alireza Sadjadi; Mehdi Nouraie; Mohammad Ali Mohagheghi; Alireza Mousavi-Jarrahi; Reza Malekezadeh; Donald Maxwell Parkin
Journal:  Asian Pac J Cancer Prev       Date:  2005 Jul-Sep

Review 6.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Human papillomavirus type 16 and 18 infection is associated with lung cancer patients from the central part of China.

Authors:  Yongping Wang; Aifeng Wang; Rui Jiang; Huaxiong Pan; Bangxing Huang; Yan Lu; Cuihuan Wu
Journal:  Oncol Rep       Date:  2008-08       Impact factor: 3.906

9.  Lung cancer.

Authors:  W D Travis; L B Travis; S S Devesa
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

Review 10.  TP53 mutations in nonsmall cell lung cancer.

Authors:  Akira Mogi; Hiroyuki Kuwano
Journal:  J Biomed Biotechnol       Date:  2011-01-18
View more
  4 in total

1.  Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development.

Authors:  Yan Yu; Xiaofei Liu; Yuxuan Yang; Xiaodan Zhao; Jianjun Xue; Weixiao Zhang; Aimin Yang
Journal:  Oncol Lett       Date:  2015-05-15       Impact factor: 2.967

Review 2.  Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention.

Authors:  Zahra Fathi; Nicholas L Syn; Jian-Guo Zhou; Raheleh Roudi
Journal:  J Hum Genet       Date:  2018-04-18       Impact factor: 3.172

3.  Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.

Authors:  Zahra Fathi; Seyed Ali Javad Mousavi; Raheleh Roudi; Farideh Ghazi
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

4.  HPV and lung cancer: A systematic review and meta-analysis.

Authors:  Julia Karnosky; Wolfgang Dietmaier; Helge Knuettel; Viola Freigang; Myriam Koch; Franziska Koll; Florian Zeman; Christian Schulz
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.